Change in the activity of glucosylceramide synthase in human hepatoma cell line with hepatitis B virus infection <i>in vitro</i>

Jian GAN; Rui YANG; Chengcheng LEI; Yating YANG; Liting YAN; Aiping TIAN; Xiaorong MAO; Lili WANG; Junfeng LI

doi:10.3969/j.issn.1001-5256.2021.04.021

Volume 37 Issue 4

Apr. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(4): 829-833

PDF( 2434 KB)

Change in the activity of glucosylceramide synthase in human hepatoma cell line with hepatitis B virus infection in vitro

DOI: 10.3969/j.issn.1001-5256.2021.04.021

1.
The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China
2.
Department of Infectious Diseases, The First Hospital of Lanzhou University, Lanzhou 730000, China
3.
The 12 th Clinical Medical College of Capital Medical University, Beijing 100000, China

Received Date: 2020-09-15
Accepted Date: 2020-10-21
Published Date: 2021-04-20

Abstract

Abstract

Objective To investigate the change in the activity of glucosylceramide synthase, the key enzyme in glycosphingolipid metabolism and synthesis, in Huh7 cells infected by hepatitis B virus (HBV) in vitro. Methods Blood samples were collected from nine previously untreated patients with acute hepatitis B who attended Department of Infectious Diseases, The First Hospital of Lanzhou University, from June to August, 2019, and the blood samples collected from seven healthy individuals who underwent physical examination were established as control. Huh7 cells were inoculated with the high-copy HBV particles (> 9.9×10⁷ IU/ml) in the serum of patients with HBV infection (infection group), and Huh7 cells co-cultured with the serum of healthy individuals were established as control group. The expression levels of HBsAg and HBV DNA in the cytoplasm of HBV-infected Huh7 cells were measured, and the correlation between GCS activity and virus was analyzed. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups, and a Pearson correlation analysis was performed. Results Compared with the control group, the infection group had a significant reduction in the number of cells, an increase in cell volume, and cell membrane fragmentation. The infection group had a significant increase in the expression of HBsAg in cytoplasm at 4 hours, 8 hours, 2 days, and 5 days after infection (P < 0.05); the expression level of HBV DNA tended to increase significantly from 4 hours after infection to 8 hours, 2 days, and 5 days after infection (16.67±11.55 IU/ml vs 112.01±25.94 IU/ml/328.01±103.50 IU/ml/101.60±49.84 IU/ml, P < 0.001), with the highest level at 2 days after infection. During HBV infection, the activity of GCS gradually increased with the increase in viral replication from 4 hours after infection (126.21±9.59 IU/ml) and reached a peak at 2 days after infection (226.53±36.27 IU/ml), with a significant difference between the infection group and the control group at 2 days after infection (226.53±36.27 IU/ml vs 136.50±15.44 IU/ml, t=3.956, P=0.016 7). The activity of GCS was positively correlated with HBV DNA level (r=0.576 8, P=0.047 1). Conclusion Huh7 cells are successfully infected with the high-copy HBV particles in the serum of patients with HBV infection, which mimics the characteristics of HBV infection in vitro to a certain degree. The activity of GCS may be associated with HBV infection, suggesting that glycosphingolipid synthesis and metabolism may be closely associated with HBV.
- Hepatitis B virus,
- Glucosylceramide Synthetase,
- In Vitro Techniques

FullText(HTML)

References(20)

References

[1]	OMATA M, KANDA T, WEI L, et al. APASL consensus statements and recommendation on treatment of hepatitis C[J]. Hepatol Int, 2016, 10(5): 702-726. DOI: 10.1007/s12072-016-9717-6.
[2]	XU ZH, LIU Y, XU DP. Advances in novel anti-HBV agents acting on different targets[J]. Infect Dis Info, 2015, 28(5): 257- 261, 283. DOI: 10.3969/j.issn.1007-8134.2015.05.001. 许智慧, 刘妍, 徐东平. 针对不同靶点的抗HBV新药研究进展[J]. 传染病信息, 2015, 28(5): 257-261, 283. DOI: 10.3969/j.issn.1007-8134.2015.05.001.
[3]	de MARTEL C, GEORGES D, BRAY F, et al. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis[J]. Lancet Glob Health, 2020, 8(2): e180-e190. DOI: 10.1016/S2214-109X(19)30488-7.
[4]	SU Y, ZHU YF, TIAN QY, et al. In vitro cell model and mouse model of HBV cccDNA[J]. J Clin Hepatol, 2019, 35(6): 1205- 1211. DOI: 10.3969/j.issn.1001-5256.2019.06.007. 苏瑜, 朱园飞, 田青右, 等. HBV cccDNA的体外细胞模型和实验小鼠模型[J]. 临床肝胆病杂志, 2019, 35(6): 1205-1211. DOI: 10.3969/j.issn.1001-5256.2019.06.007.
[5]	NOORDEEN F, SCOUGALL CA, GROSSE A, et al. Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection[J]. PLoS One, 2015, 10(11): e0140909. DOI: 10.1371/journal.pone.0140909.
[6]	FLETCHER SP, CHIN DJ, GRUENBAUM L, et al. Intrahepatic transcriptional signature associated with response to interferon-α treatment in the woodchuck model of chronic hepatitis B[J]. PLoS Pathog, 2015, 11(9): e1005103. DOI: 10.1371/journal.ppat.1005103.
[7]	NI Y, LEMPP FA, MEHRLE S, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes[J]. Gastroenterology, 2014, 146(4): 1070-1083. DOI: 10.1053/j.gastro.2013.12.024.
[8]	HANNUN YA, OBEID LM. Sphingolipids and their metabolism in physiology and disease[J]. Nat Rev Mol Cell Biol, 2018, 19(3): 175-191. DOI: 10.1038/nrm.2017.107.
[9]	LIU YY, HILL RA, LI YT. Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance[J]. Adv Cancer Res, 2013, 117: 59-89. DOI: 10.1016/B978-0-12-394274-6.00003-0.
[10]	LI JF, ZHENG SJ, LIU S, et al. Impact of UGCG siRNA on 7702 hepatocyte proliferation in vitro[J]. J Pract Hepatol, 2018, 21(5): 697-700. DOI: 10.3969/j.issn.1672-5069.2018.05.011. 李俊峰, 郑素军, 刘霜, 等. 葡萄糖神经酰胺葡萄糖基转移酶siRNA对7702肝细胞增殖的影响及机制研究[J]. 实用肝脏病杂志, 2018, 21(5): 697-700. DOI: 10.3969/j.issn.1672-5069.2018.05.011.
[11]	WEGNER MS, GRUBER L, MATTJUS P, et al. The UDP-glucose ceramide glycosyltransferase (UGCG) and the link to multidrug resistance protein 1 (MDR1)[J]. BMC Cancer, 2018, 18(1): 153. DOI: 10.1186/s12885-018-4084-4.
[12]	WANG T, WEI J, WANG N, et al. The glucosylceramide synthase inhibitor PDMP sensitizes pancreatic cancer cells to MEK/ERK inhibitor AZD-6244[J]. Biochem Biophys Res Commun, 2015, 456(3): 821-826. DOI: 10.1016/j.bbrc.2014.12.019.
[13]	FAVRE D, PETIT MA, TRÉPO C. Latent hepatitis B virus (HBV) infection and HBV DNA integration is associated with further transformation of hepatoma cells in vitro[J]. ALTEX, 2003, 20(3): 131-142.
[14]	ZHONG G, YAN H, WANG H, et al. Sodium taurocholate cotransporting polypeptide mediates woolly monkey hepatitis B virus infection of Tupaia hepatocytes[J]. J Virol, 2013, 87(12): 7176-7184. DOI: 10.1128/JVI.03533-12.
[15]	CHOI BH, PARK CJ, RHO HM. Insulin activates the hepatitis B virus X gene through the activating protein-1 binding site in HepG2 cells[J]. DNA Cell Biol, 1998, 17(11): 951-956. DOI: 10.1089/dna.1998.17.951.
[16]	ZHENG SJ, QU F, LI JF, et al. Serum sphingomyelin has potential to reflect hepatic injury in chronic hepatitis B virus infection[J]. Int J Infect Dis, 2015, 33: 149-155. DOI: 10.1016/j.ijid.2015.01.020.
[17]	ZHANG JY, QU F, LI JF, et al. Up-regulation of plasma hexosylceramide (d18: 1/18: 1) contributes to genotype 2 virus replication in chronic hepatitis C: A 20-year cohort study[J]. Medicine (Baltimore), 2016, 95(23): e3773. DOI: 10.1097/MD.0000000000003773.
[18]	WERR M, PRANGE R. Role for calnexin and N-linked glycosylation in the assembly and secretion of hepatitis B virus middle envelope protein particles[J]. J Virol, 1998, 72(1): 778-782. DOI: 10.1128/JVI.72.1.778-782.1998.
[19]	XU J, ZHAO W, SUN J, et al. Novel glucosylceramide synthase inhibitor based prodrug copolymer micelles for delivery of anticancer agents[J]. J Control Release, 2018, 288: 212-226. DOI: 10.1016/j.jconrel.2018.09.011.
[20]	LEVERY SB, MOMANY M, LINDSEY R, et al. Disruption of the glucosylceramide biosynthetic pathway in Aspergillus nidulans and Aspergillus fumigatus by inhibitors of UDP-Glc: Ceramide glucosyltransferase strongly affects spore germination, cell cycle, and hyphal growth[J]. FEBS Lett, 2002, 525(1-3): 59-64. DOI: 10.1016/s0014-5793(02)03067-3.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (415) PDF downloads(22)

Change in the activity of glucosylceramide synthase in human hepatoma cell line with hepatitis B virus infection in vitro

DOI: 10.3969/j.issn.1001-5256.2021.04.021

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Change in the activity of glucosylceramide synthase in human hepatoma cell line with hepatitis B virus infection in vitro

DOI: 10.3969/j.issn.1001-5256.2021.04.021

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content